The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: Assessment by two different detection methods

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1907-1915

  Lucia, Eugenio ^a   Martino, Bruno ^b   Mammi, Corrado ^b   Vigna, Ernesto ^a   Mazzone, Carla ^a   Gentile, Massimo ^a   Qualtieri, Gabriele ^a   Bisconte, Maria Grazia ^a   Naccarato, Maria ^a   Gentile, Carlo ^a   Laganà, Carmelo ^b   Romeo, Francesco ^a   Neri, Antonino ^c   Nobile, Francesco ^b   Morabito, Fortunato ^a  

^a Azienda Ospedaliera   (Italy)

^b Azienda Ospedaliera B   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Allele specific polymerase chain reaction; bcr abl negative chronic myeloproliferative disorders; JAK2 V617F mutation; Polycythemia vera; TaqMan assay

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE 2;

ALLELE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; HEMATOCRIT; HUMAN; HUMAN CELL; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MUTATION RATE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BLOOD CELL COUNT; CHRONIC DISEASE; HEMATOCRIT; HUMANS; INCIDENCE; JANUS KINASE 2; METHODS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 55049115410     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802290652     Document Type: Conference Paper

References (37)

1. Dameshek, W. (1951) Some speculations on the myeloproliferative syndromes. Blood, 6, pp. 372-375.
2. Campbell, P. J. and Green, A. R. (2006) The myeloproliferative disorders. N Engl J Med, 355, pp. 2452-2466.
3. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N. Swanton, S. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, pp. 1054-1061.
4. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G. Huntly, B. J. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, pp. 387-397.
5. James, C., Ugo, V., Le Couedic, J P, Staerk, J., Delhommeau, F. Lacout, C. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, pp. 1144-1148.
6. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R. Passweg, J. R. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 352, pp. 1779-1790.
7. Nelson, M. E. and Steensma, D. P. (2006) JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?. Leuk Lymphoma, 47, pp. 177-194.
8. McClure, R., Mai, M. and Lasho, T. (2006) Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia, 20, pp. 168-171.
9. Steensma, D. P., Dewald, G. W., Lasho, T. L., Powell, H. L., McClure, R. F. Levine, R. L. et al. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood, 106, pp. 1207-1209.
10. Levine, R. L., Loriaux, M., Huntly, B. J., Loh, M. L., Beran, M. Stoffregen, E. et al. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, pp. 3377-3379.
11. Sidon, P., El Housni, H, Dessars, B. and Heimann, P. (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia, 20, p. 1622.
12. Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q. Krantz, S. B. et al. (2007) JAK2(V617F): Prevalence in a large Chinese hospital population. Blood, 109, pp. 339-342.
13. Greiner, T. C. (2006) Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. Am J Clin Pathol, 125, pp. 651-653.
14. Lasho, T. L., Mesa, R., Gilliland, D. G. and Tefferi, A. (2005) Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol, 130, pp. 797-799.
15. Tefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A. Li, C. Y. et al. (2005) The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol, 131, pp. 320-328.
16. Passamonti, F., Rumi, E., Pietra, D., Della Porta, M. G., Boveri, E. Pascutto, C. et al. (2006) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 107, pp. 3676-3682.
17. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q. Krantz, S. B. et al. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem, 280, pp. 22788-22792.
18. Sidon, P., Heimann, P., Lambert, F., Dessars, B., Robin, V. and El Housni, H (2006) Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. Clin Chem, 52, pp. 1436-1438.
19. Tan, A. Y., Westerman, D. A. and Dobrovic, A. (2007) A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol, 127, pp. 977-981.
20. Steensma, D. P. (2006) JAK2 V617F in myeloid disorders: Molecular diagnostic techniques and their clinical utility: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn, 8, pp. 397-411.
21. Cheung, B., Radia, D., Pantelidis, P., Yadegarfar, G. and Harrison, C. (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol, 132, pp. 244-245.
22. Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L. Marsden, J. T. et al. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet, 366, pp. 1945-1953.
23. Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M. Lee, S. J. et al. (2005) JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol, 131, pp. 208-213.
24. Campbell, P. J., Griesshammer, M., Dohner, K., Dohner, H., Kusec, R. Hasselbalch, H. C. et al. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, pp. 2098-2100.
25. Vardiman, J. W., Harris, N. L. and Brunning, R. D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, pp. 2292-2302.
26. Popat, U., Frost, A., Liu, E., Guan, Y., Durette, A. Reddy, V. et al. (2006) High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood, 107, pp. 3486-3488.
27. Patel, R. K., Lea, N. C., Heneghan, M. A., Westwood, N. B., Milojkovic, D. Thanigaikumar, M. et al. (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology, 130, pp. 2031-2038.
28. Jones, A. V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C. Zhang, L. et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, pp. 2162-2168.
29. Gattenlohner, S., Peter, C., Bonenge, M., Einsele, H., Bargou, R. Muller-Hermelink, H. K. et al. (2007) Detecting the JAK2 V617F mutation in fresh and 'historic' blood and bone marrow. Leukemia, 21, pp. 1599-1602.
30. Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J. T. Verstovsek, S. et al. (2005) JAK2 mutation 1849G
31. Tefferi, A. and Vardiman, J. W. (2007) The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol, 14, pp. 115-122.
32. Tefferi, A. and Gilliland, D. G. (2005) The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: Status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc, 80, pp. 947-958.
33. James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couedic, J. P. Giraudier, S. et al. (2006) Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia, 20, pp. 350-353.
34. Hammond, E., Shaw, K., Carnley, B., P'ng, S., James, I. and Herrmann, R. (2007) Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn, 9, pp. 242-248.
35. Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A. Ponziani, V. et al. (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia, 21, pp. 1952-1959.
36. Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G. Marchioli, R. et al. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110, pp. 840-846.
37. Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M. Ponziani, V. et al. (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 19, pp. 1847-1849.